IRADIMED Names John McCreery Chief Operating Officer
March 30 2017 - 9:41AM
IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John
McCreery has been appointed Chief Operating Officer, a new position
within the Company. Mr. McCreery will have primary responsibility
over the regulatory, manufacturing and engineering departments of
the Company.
Mr. McCreery, 62, is currently a tenured professor in operations
and innovation at North Carolina State University’s College of
Management. At NC State, he works with a wide variety of
organizations – from start-ups to multinational firms – in
operational excellence, innovation management, and leadership
development initiatives. He has also served as Director of a
cross-continent US-Europe-China graduate program in global
innovation management. Prior to joining NC State, Mr. McCreery held
roles in engineering, manufacturing, IT systems consulting, and
company leadership, including Chief Operating Officer at Invivo
Research. He received his undergraduate degree in Biomedical
Engineering, with Honors, from Case Western Reserve University, an
MBA from the University of Michigan, and a Ph.D. in operations
management from Ohio State University.
“John is a trusted leader and we are excited to have him join us
as Chief Operating Officer. He brings deep knowledge and experience
in the areas of regulatory affairs, manufacturing and engineering.
We look forward to his arrival and leadership. Additionally, with
John in place, I will be able to dedicate more time focusing on
sales initiatives and new product development,” said Roger Susi,
President and Chief Executive Officer of the Company.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of MRI
compatible medical devices. We are the only known provider of
non-magnetic intravenous (IV) infusion pump systems that are
specifically designed to be safe for use during magnetic resonance
imaging (MRI) procedures. We were the first to develop an infusion
delivery system that largely eliminates many of the dangers and
problems present during MRI procedures. Standard infusion pumps
contain magnetic and electronic components which can create radio
frequency (RF) interference and are dangerous to operate in the
presence of the powerful magnet that drives an MRI system. Our
patented MRidium® MRI compatible IV infusion pump system has been
designed with a non-magnetic ultrasonic motor, uniquely-designed
non-ferrous parts and other special features in order to safely and
predictably deliver anesthesia and other IV fluids during various
MRI procedures. Our pump solution provides a seamless approach that
enables accurate, safe and dependable fluid delivery before, during
and after an MRI scan, which is important to critically-ill
patients who cannot be removed from their vital medications, and
children and infants who must generally be sedated in order to
remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system
has been designed with non-magnetic components and other special
features in order to safely and accurately monitor a patient’s
vital signs during various MRI procedures. The IRADIMED 3880
system operates dependably in magnetic fields up to 30,000 gauss,
which means it can operate virtually anywhere in the MRI scanner
room, including in very close proximity to the MRI scanner bore.
The IRADIMED 3880 has a compact, lightweight design allowing
it to travel with the patient from their critical care unit, to the
MRI and back, resulting in increased patient safety through
uninterrupted vital signs monitoring and decreasing the amount of
time critically ill patients are away from critical care units. The
features of the IRADIMED 3880 include: wireless ECG with
dynamic gradient filtering; wireless SpO2 using Masimo® algorithms;
non-magnetic respiratory CO2; non-invasive blood pressure; patient
temperature, and; optional advanced multi-gas anesthetic agent unit
featuring continuous Minimum Alveolar Concentration measurements.
The IRADIMED 3880 MRI compatible patient vital signs
monitoring system has an easy-to-use design and allows for the
effective communication of patient vital signs information to
clinicians. Our 3880 MRI compatible patient vital signs monitoring
system is currently available to international customers. Once we
receive FDA 510(k) clearance, the 3880 will be available to U.S.
customers. We currently anticipate commencing marketing the 3880 to
U.S. customers in the third quarter of 2017.
For more information please visit www.iradimed.com.
Media Contact:
Chris Scott
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jul 2023 to Jul 2024